Skip to main content

Table 2 Variants associated with PFS in multivariate Cox proportional hazards regression model

From: Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Variables

B

SE

Wald

P

HR

95.0 % CI for HR

Pathology

 Non-adenocarcinoma

    

1.00

 

 Adenocarcinoma

−1.26

0.54

5.36

0.021

0.285

0.10~0.83

ECOG PS

 ≥2

    

1.00

 

 0–1

−1.01

0.53

3.71

0.054

0.363

0.13~1.02

Groups

 Stable group

    

1.00

 

 Ascend group

−0.70

0.28

6.43

0.011

0.498

0.30~0.85

  1. PFS progression-free survival, ECOG Eastern Cooperative Oncology Group, PS performance status
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us